Media coverage about Onconova Therapeutics (NASDAQ:ONTX) has trended somewhat positive recently, according to Accern. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Onconova Therapeutics earned a coverage optimism score of 0.09 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 44.8924427167141 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the news articles that may have impacted Accern’s scoring:

ONTX has been the topic of several research reports. HC Wainwright initiated coverage on Onconova Therapeutics in a research report on Monday, October 9th. They issued a “buy” rating and a $6.00 target price on the stock. Maxim Group restated a “buy” rating and issued a $6.00 target price on shares of Onconova Therapeutics in a research report on Thursday, November 2nd. Finally, Zacks Investment Research downgraded Onconova Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, December 12th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $7.33.

Onconova Therapeutics (ONTX) traded down $0.01 during trading hours on Wednesday, hitting $1.67. The company had a trading volume of 107,100 shares, compared to its average volume of 168,517. Onconova Therapeutics has a 12-month low of $1.21 and a 12-month high of $3.88. The firm has a market capitalization of $17.99, a PE ratio of -0.55 and a beta of 0.10.

Onconova Therapeutics (NASDAQ:ONTX) last posted its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.02. Onconova Therapeutics had a negative return on equity of 558.97% and a negative net margin of 2,855.94%. The firm had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.29 million. research analysts anticipate that Onconova Therapeutics will post -2.82 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Onconova Therapeutics (ONTX) Getting Somewhat Positive Press Coverage, Study Finds” was first published by Daily Political and is the property of of Daily Political. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at

Onconova Therapeutics Company Profile

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.

Insider Buying and Selling by Quarter for Onconova Therapeutics (NASDAQ:ONTX)

Receive News & Ratings for Onconova Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics and related companies with's FREE daily email newsletter.